Tempest Therapeutics (TPST) Proxy filing summary

Executive summary

• Reconvened special meeting adjourned on October 14, 2026, after the proposal lacked sufficient votes; next session set for November 12, 2026, at 2:00 p.m. ET.

• 11,004,101 shares, or 74.3% of 14,806,997 shares outstanding on the May 28, 2026 record date, were represented, constituting a quorum.

Voting matters and shareholder proposals

• Stockholders are asked to approve a charter amendment replacing specified supermajority voting requirements and permitting stockholder action by written consent.

• Approval requires affirmative votes representing at least 75% of the votes all stockholders could cast in an annual election of directors or a class of directors.

• The proposal is unchanged; the meeting was adjourned to allow more time to vote and encourage broader participation.

Shareholder rights and capital structure

• Previously submitted proxies remain valid for the reconvened meeting unless properly revoked; stockholders who do not wish to change an existing vote need take no action.

• The record date remains May 28, 2026; the reconvened meeting will be held by live webcast, with the same access code as the original meeting.